Rapid RV/LV
by RapidAI (formerly iSchemaView)
· Based in United States →
— AI-powered rapid assessment of pulmonary embolism severity.
Contact vendor for pricing information.
Regulatory Status Disclosed
Overview
Rapid RV/LV by RapidAI is an FDA-cleared artificial intelligence (AI) software designed to assist physicians in the rapid assessment of pulmonary embolism (PE) severity. It analyzes volumetric Computed Tomography Pulmonary Angiography (CTPA) acquisitions to automatically measure the maximal diameters of the right and left ventricles of the heart and report their ratio for adult patients. This tool is a key component of the broader Rapid PE solution, enabling healthcare teams to quickly conduct risk stratification for patients exhibiting right heart strain. By providing annotated images with ventricular measurements within minutes of a scan, Rapid RV/LV aims to reduce inter-rater variability and streamline the PE care pathway from diagnosis through treatment.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered analysis of CTPA images
- Automated measurement of right and left ventricle diameters
- Calculation of RV/LV ratio
- Annotated images showing ventricular measurements
- Rapid results (within minutes of scan)
- Reduces inter-rater variability
- Integration with Rapid PE solution
- Triage and notification capabilities (as part of the broader Rapid platform)
- DICOM viewer for AI outputs and source imaging (via Rapid mobile app)
- Secure sharing of time-critical scans (via integration with communication apps)
Use Cases
- Risk stratification for pulmonary embolism (PE) patients with right heart strain
- Assessing pulmonary embolism severity
- Expediting diagnosis and treatment plans for PE
- Identifying patients who would benefit from further PE treatment
- Streamlining PE care pathways
- Supporting clinical decision-making in acute PE cases
What Physicians Need to Know
Echocardiography AI Features
While Rapid RV/LV focuses on CT scans, AI tools for echocardiography are being developed to assess RV function. For example, EchoNet-RV automates the assessment of Right Ventricular Fractional Area Change (RVFAC) with strong potential for evaluating RV function and disease surveillance. Another deep learning framework uses echocardiograms for automated RV functional assessment, including frame-level ventricular segmentation and beat-by-beat estimation of fractional area change (FAC), and classification of RV-related disease. These tools aim to enhance diagnostic consistency, reduce manual workload, and support earlier intervention. AI-powered echocardiography can also provide real-time ventricular volume tracking, offering insights into how the heart adapts to stress, activity, or disease.
Cardiac CT/MRI Analysis
Rapid RV/LV uses AI to analyze Computerized Tomography Pulmonary Angiograms (CTPAs) to automatically calculate the RV/LV ratio within minutes. This helps in the risk stratification of patients with right heart strain, particularly in the context of pulmonary embolism (PE). Cardiac CT can provide accurate and reproducible left ventricular (LV) and RV volume parameters compared with MRI, making it a reliable alternative for patients unsuitable for MRI.
Arrhythmia Detection Accuracy
Rapid RV/LV itself does not perform arrhythmia detection. However, AI models for arrhythmia detection from ECG signals have shown high accuracy, with some achieving 99.5% accuracy for separating healthy individuals from those with ventricular arrhythmia and 98% accuracy for detecting various arrhythmias.
Heart Failure Risk Prediction
Rapid RV/LV assists in risk stratification for patients with right heart strain, which is relevant to heart failure. Right ventricular failure (RVF) is a significant cause of morbidity and mortality, especially after left ventricular assist device (LVAD) implantation. Echocardiographic measurements like the RV/LV diameter ratio (≥0.75) are independently associated with a higher risk for RVF in LVAD patients. AI models are also being developed to predict RV dysfunction and future cardiovascular disease from echocardiograms. For instance, predicted dilated right ventricles were associated with a twofold increased risk of death within five years.
Coronary Artery Assessment
While Rapid RV/LV focuses on RV/LV ratio from CTPA, cardiac CT can be used for the evaluation of coronary arteries. AI is also being explored to assess right ventricular systolic dysfunction from coronary angiograms. DeepRV is an open-weight video-based deep neural network that predicts right ventricular systolic function (RVSF) from routine left and right coronary angiograms.
Cardiac Monitoring Integration
RapidAI's platform offers team workflow across the entire care continuum and EMR integration for a single source of truth. The Rapid Enterprise™ Platform allows access to trusted partner AI. Real-time ventricular monitoring with wearable ECG devices is an area of ongoing research, aiming to provide a complete picture of electrical and mechanical heart function. Implantable sensors and wearables can transmit real-time data to healthcare providers for early intervention.
AHA/ACC Guideline Alignment
The RV/LV ratio is recommended by guidelines, such as the 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults, among echocardiographic parameters used to assess RV dysfunction in acute PE. An RV/LV ratio ≥ 1.0 is considered indicative of right heart strain.
Real-Time Alert Capability
Rapid RV/LV provides automated RV/LV ratio calculation within minutes of a CTPA scan, enabling quicker risk stratification and potentially faster clinical decision-making for PE patients with right heart strain. This can lead to prompt notification of suspected PE patients. The RV/LV diameter ratio offers real-time risk stratification and is a predictor of low cardiac index in patients with acute PE. Automated RV/LV ratio on CTPA exams in acute positive PE cases can be used to assess prognosis and augment early triage decisions.
Physician Tip
Rapid RV/LV can help quickly identify patients with potential right heart strain from CTPA scans, which is crucial for risk stratification in pulmonary embolism. The automated RV/LV ratio can reduce diagnostic time and standardize measurements, aiding in faster treatment decisions. An RV/LV ratio ≥ 1.0 suggests right heart strain and warrants further assessment. While the tool is valuable for PE, remember that RV assessment can be complex due to its unique anatomy, and should be integrated with other clinical findings and validated risk assessments.
Rapid RV/LV is a component of the Rapid PE solution and integrates with the Rapid Enterprise™ Platform. This platform connects radiology, specialists, and care teams, and allows for EMR integration for a single source of truth. It also supports access to trusted partner AI solutions.
Details
| Category | Cardiology AI, Radiology & Imaging AI |
| Pricing | Contact vendor for pricing information. |
| Deployment | On-premises (dedicated server or virtual machine) or hybrid (on-premises/cloud with secure link to cloud), connecting to hospital LAN/firewall. |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Pulmonology, Radiology |
What the Web Says
Rapid RV/LV by RapidAI is an AI-powered tool designed to quickly assess the severity of pulmonary embolism (PE) by automatically calculating the ratio between the right ventricle (RV) and the left ventricle (LV) from CTPA scans. This FDA-cleared software aims to help physicians prioritize patients, accelerate treatment decisions, and standardize RV/LV measurements, ultimately improving patient outcomes.
Overall: MixedStrengths
- Rapid assessment of PE severity and right heart strain.
- Automates RV/LV ratio calculation, reducing variability and standardizing measurements.
- Helps physicians quickly prioritize patients and accelerate treatment decisions.
- Integrates with existing hospital IT systems like PACS and EHRs.
- Facilitates communication and collaboration among care teams through mobile and web apps.
- Provides detailed insights beyond simple detection, including precise location, volume, and size of anomalies.
Limitations
- Cost-effectiveness of the product is currently unknown.
- Lack of transparency regarding machine-learning model development and potential for bias.
- Mobile app experiences frequent glitches, login issues, and unreliable notifications.
- Some radiologists find AI tools, including LVO detection, to be unhelpful or generate too many false positives/negatives.
- Highly negative employer reviews citing toxic executive team, mental abuse, and micro-management.
- Poor pay and benefits, and limited job security and advancement opportunities according to some employees.
Based on reviews from: AuntMinnie.com, healthaidb.com, physicianaitools.com, dicardiology.com, theimagingwire.com, calameo.com
Last updated: 2026-10-30
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Rapid RV/LV
Press & Coverage
respiratory-therapy.com
FDA Clearance for Rapid RV/LV Pulmonary Embolism Care Solution
RapidAI received FDA clearance for its Rapid RV/LV tool, which uses AI to analyze CTPA scans and quickly calculate the RV/LV ratio, a key indicator of pulmonary embolism severity, to help physicians with risk stratification and faster decision-making.
2023-02
massdevice.com
FDA clears pulmonary embolism diagnostic, triage tech from RapidAI
RapidAI announced FDA 510(k) clearance for its Rapid RV/LV tool, designed to assess pulmonary embolism (PE) severity by quickly calculating the right ventricle to left ventricle (RV/LV) ratio from CT pulmonary angiograms (CTPAs) using AI.
2023-02
auntminnie.com
RapidAI receives FDA clearance for Rapid RV/LV
RapidAI's Rapid RV/LV software, part of its Rapid PE detection and analysis suite, has received FDA 510(k) clearance to automatically calculate the RV/LV ratio on CT pulmonary angiograms, aiding in the assessment of pulmonary embolism severity.
2023-02
mobilehealthtimes.com
RapidAI Enhances Pulmonary Embolism Care Solution with FDA 510(k) Clearance for Rapid RV/LV
RapidAI has received FDA 510(k) clearance for its Rapid RV/LV tool, which enhances its pulmonary embolism care solution by providing an AI-powered assessment of the RV/LV ratio to quickly identify patients with right heart strain.
2023-03
rapidai.com
Rapid RV/LV
Rapid PE RV/LV is presented as a component of RapidAI's pulmonary embolism AI solution, designed to help identify treatment-eligible patients faster and streamline workflows.
unknown
vascularnews.com
Computer-assisted vacuum thrombectomy system for patients with pulmonary embolism demonstrates 'rapid, statistically significant' improvement in RV/LV ratio
An interim analysis of the STRIKE-PE study showed that computer-assisted vacuum thrombectomy significantly reduced the RV/LV ratio in pulmonary embolism patients, indicating rapid improvement.
2023-11
nih.gov
Automated CT-based right ventricular to left ventricular diameter ratio for the detection of pulmonary hypertension
This study investigated the diagnostic accuracy of an automated AI-derived right ventricle/left ventricle diameter ratio (RV/LV) computed tomography pulmonary angiography (CTPA) analysis tool for detecting pulmonary hypertension.
2022-04
nih.gov
Automated right ventricular to left ventricular ratio on CT pulmonary angiogram is associated with adverse outcomes in acute pulmonary embolism
A study found that an automated RV/LV ratio greater than 1 on CT pulmonary angiograms in acute PE cases is associated with a higher likelihood of ICU admission and interventional radiology procedures.
2026-04
Videos
Product demos, reviews, and walkthroughs for Rapid RV/LV.
No videos found. Search YouTube directly
Frequently Asked Questions
Rapid RV/LV is an AI-powered tool that analyzes CT Pulmonary Angiograms (CTPAs) to automatically calculate the ratio between the right ventricle (RV) and the left ventricle (LV) within minutes. This ratio is a crucial indicator of pulmonary embolism (PE) severity and helps physicians quickly assess for right heart strain, enabling faster risk stratification and treatment decisions for PE patients.
Yes, Rapid RV/LV received FDA 510(k) clearance in February 2023. This clearance means the tool has been deemed substantially equivalent to a legally marketed device, allowing it to be used clinically to aid physicians in quickly assessing PE severity and identifying patients with right heart strain.
While AI-based measurements can augment early triage decisions, studies have shown that manual RV/LV ratio measurements can have weak interobserver agreement and may not always correlate with mortality. The accuracy of AI tools can also vary, and experienced human readers may still demonstrate higher accuracy in certain complex cases. It's important to note that an RV/LV ratio ≥ 1.0 indicates right heart strain, but further assessment is warranted.
Yes, manual measurement of RV/LV ratios on CTPA images is a traditional method, though it can be subject to variability. Other AI-powered solutions exist in the market that also aim to provide automated RV/LV ratio calculations. For instance, Imbio offers Pulmonary Hypertension Assessment (PHA™) which also processes CTPA scans for RV/LV ratios. Additionally, other AI software like Viz.ai also offers RV/LV ratio algorithms.
Rapid RV/LV is designed to integrate with the broader Rapid PE solution, streamlining the care pathway from scan to diagnosis and treatment. It aims to reduce variability and standardize RV/LV measurements, providing results within minutes and facilitating quicker communication among care teams. As an FDA-cleared device, it adheres to regulatory standards for medical devices, but specific compliance details would be part of the implementation and usage agreements with RapidAI.
Compare Rapid RV/LV
VS
Rapid RV/LV vs PMcardio
Rapid RV/LV and PMcardio are both cardiology AI tools, but they focus on different diagnostic modalities and conditions. Rapid RV/LV analyzes CTPA scans to assess pulmonary embolism severity…
VS
Rapid RV/LV vs EchoNext
Both Rapid RV/LV and EchoNext are FDA-cleared AI tools in cardiology, but they focus on different diagnostic modalities and conditions. Rapid RV/LV specializes in analyzing CTPA scans for…
VS
SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION vs Rapid RV/LV
Tool A, SensiCardiac Mobi, is designed to assist in diagnosing heart murmurs by analyzing acoustic heart signals from electronic stethoscopes. In contrast, Tool B, Rapid RV/LV, focuses on…
VS
Rapid RV/LV vs IM007
Tool A is an AI-powered solution for rapid assessment of pulmonary embolism severity by analyzing CTPA scans, focusing on acute diagnostic support. In contrast, Tool B is a…
Suggest an Edit → | Report an issue
| Last Verified: 2026-04-18 | First Added: 2026-04-18